test

Developmental Therapeutics

Terri Lynn Parker MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Clinical Interests

Benign and Malignant Hematology; Hospice and Palliative Medicine


Board Certifications

2012
Hematology (Internal Medicine), Board Certified
2008
Internal Medicine, Board Certified
2010
Hospice & Palliative Medicine, Board Certified

Patient Care Locations

terri_parkerfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Non-Hodgkin's LymphomaOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Leukemia, not otherwise specified, Leukemia, other, and Myeloid and Monocytic LeukemiaA Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Myeloid and Monocytic LeukemiaA Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Multiple MyelomaA Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

More Clinical Trials...

Edit Profile